PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Rotigotine - Restless Leg Syndrome

PAD Profile : Rotigotine - Restless Leg Syndrome

Keywords :
dopamine receptor agonists
Brand Names Include :
Neupro

Traffic Light Status

Status 1 of 1.

Status :
Green
Important Preferred
Formulations :
  • Patches
Important Information :
Patients with severe symptoms, who are obese, co-morbid depression, increased risk of falls or cognitive impairment. Consider use of patch if significant daytime symptoms as it has a long duration of action.
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date
Evidence Review
01 November 2021

Committee Recommendations

Date
Committee Name
Narrative
07 November 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

Rotigotine is recommended as a FIRST line option for the treatment of Restless Leg Syndrome, as per CKS guidance.

Link to CKS page - https://cks.nice.org.uk/restless-legs-syndrome

Associated BNF Codes

04. Central Nervous System
04.09.01. Dopaminergic drugs used in parkinsonism
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More